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Abstract
Introduction—To detect a predictive protein profile that distinguishes between IL-2 therapy
responders and non-responders among metastatic RCC patients we used surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry (SELDI TOF-MS).
Materials and Methods—Protein extracts of 56 metastatic clear cell RCC patients obtained
from radical nephrectomy specimens and prior to IL-2 therapy were applied to protein chip arrays
of different chromatographic properties and analyzed using SELDI TOF-MS. A class prediction
algorithm was applied to identify a subset of protein peaks whose expression values were
associated with IL-2 response status. Multivariate analysis was performed to assess the association
between the proteomic profile and the IL-2 response status controlling for the effect of
lymphadenopathy.
Results—From a total of 513 protein peaks we discovered a predictor set of 11 peaks that
performed optimally for predicting IL-2 response status (86 % accuracy, Fisher’s p<0.004,
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permutation p<0.01). The results were validated on an independent data set with an overall
accuracy of 72% (p < 0.05, permutation p<0.01). On multivariate analysis the proteomic profile
was significantly associated with IL-2 response when corrected for lymph node status (p< 0.04).
Conclusions—We have identified and validated a proteomic pattern that is an independent
predictor of IL-2 response. The ability to predict the probability of IL-2 response could permit
targeted selection of patients most likely to respond to IL-2, while avoiding unwanted toxicities in
patients less likely to respond. This proteomic predictor has the potential to significantly aid
clinicians in the decision making of appropriate therapy for metastatic RCC patients.
Keywords
proteomics; metastatic Renal Cell Cancer; IL-2 therapy; surfaced-enhanced laser desorption/
ionization time-of-flight mass spectrometry; biomarkers
Purpose
Renal Cell Cancer (RCC) has a heterogeneous clinical presentation with up to 30%
metastatic cases at initial diagnosis and approximately 30% of initially organ-confined cases
developing metastases during follow-up at variable intervals1. Recently FDA approved oral
agents for metastatic RCC offer improved progression free and overall survival, but
essentially no complete responses2. Aggressive treatment with radical nephrectomy and
immunotherapy has also been shown to provide a survival benefit in metastatic RCC
patients3, 4, and retrospective data suggest that five-year survival rates were improved when
IL-2 was used as adjunctive immunotherapy instead of IFN-α (19.6% vs. 10%)5. Although
the administration of IL-2 offers the possibility of durable CRs, it is associated with
considerable toxicity, while only a small subset of patients respond to therapy3. Possible
biomarkers for RCC such as carbonic anhydrase-IX (CA IX), Ki67 or PTEN have been
published6, 7. However, there is no reliable single marker available to identify those patients
that are more likely to respond to IL-2 therapy, although factors such as regional
lymphadenopathy, expression of CA-IX8, 9, and selective pathologic subtypes have been
proposed10.
Proteomics is an emerging field of science that attempts to study proteins in a massively
parallel scale. Mass spectrometry (MS) based technologies such as MALDI (matrix assisted
laser desorption /ionization), Surface enhanced laser/desorption ionization time of flight
(SELDI-TOF MS), electrospray and ion trap have become the methods of choice in
biomarker discovery and enable the separation of proteins and peptides according to their
mass over charge (m/z) ratio. However, due to the large variations in concentrations of the
proteome in tissues and bodily fluids most of the mass spectrometric approaches are not
amenable to large numbers of patient samples. SELDI-TOF MS is one of few proteomic
technologies suitable for high-throughput protein profile generation across a wide range of
molecular weights, while proteins are retained on protein chips based on their binding
affinity to the chip surface. While SELDI appears to be more sensitive in the low-mass
range, which holds valuable information for biomarker discovery, SELDI by itself cannot
identify protein IDs. Nevertheless, we have previously developed and validated a robotic
approach to determine protein profiles with high reproducibility by SELDI-TOF MS11, 12. In
the current study our objective was to detect a protein profile that distinguishes between
IL-2 treatment responders and nonresponders among metastatic RCC patients using SELDI
TOF-MS.
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Materials and Methods
Patients and tumor samples
56 prospectively archived frozen tissue samples from primary tumors of patients with
metastatic clear cell RCC were obtained from the UCLA Kidney Cancer Program with
approval from the institutional review board at UCLA and Beth Israel Deaconess Medical
Center, Boston. All patients had undergone radical nephrectomy and adjunctive
immunotherapy with recombinant IL-2 based therapy, and were evaluable for response.
High dose IL-2 regimen consisted of up to two treatment cycles, each comprised of two
treatment admissions separated by 10 days. For each admission, subjects were treated with
600,000 IU/kg via intravenous bolus infusion every 8 hours for up to 14 doses during a five
day hospitalization. Response status was defined according to standard criteria defined at the
time of the patients’ evaluation and prior to the widespread adoption of RECIST (Response
Evaluation Citeria in Solid Tumors).
Protein isolation
Approximately 50mg tissue was ground and lysed in 250µl lysis buffer consisting of 8M
Urea, 2% CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-propansulfonat),5mM
DTT and 1% protease inhibitors. This mixture was vortexed and lyzed with a micro-pestle
for 10 minutes and centrifuged at 10,000 × g at 4° C. The supernatant was then collected and
the protein concentration was measured by Bradford assay. The protein concentration was
normalized to 1µg/µl.
Mass Spectrometry
SELDI TOF-MS was performed using sample duplicates with the arrays described below.
The entire procedure was carried out by a fully automated liquid-handling robot (Biomek
FX™, Beckman Coulter).
Reversed Phase Chromatography
Hydrophobic protein arrays (H50 ProteinChip™ arrays; Ciphergen) were bulk washed with
50% acetonitrile (HPLC Grade; Aldrich) for 2 × 5 min, then loaded onto a 192-well
bioprocessor (Ciphergen) and equilibrated with 10% acetonitrile/ 0.1% trifluoroacetic acid
(Fisher Scientific). Each bioprocessor holds up to twelve 16-spot protein arrays and creates
100 µl wells above each spot. Ten µl of cell lysate were applied together with 50 µl binding
buffer consisting of 10% acetonitrile/0.1% trifluoroacetic acid onto each array spot, and
incubated for an hour. Array spots were washed 3 × 5 min with 75 µl 10% acetonitrile/ 0.1%
trifluoroacetic acid, and 1 × 5 min with 75 µl water.
Cationic Exchange Chromatography
Weak cationic exchange chromatography protein arrays (CM10 ProteinChip™ arrays;
Ciphergen) were pretreated with 10mM HCl for 5 min, and then rinsed with HPLC grade
water. Subsequently, the arrays were loaded onto a 192-well bioprocessor, and equilibrated
with 20mM ammonium acetate/0.1% Triton X-100 (Sigma), pH 6.0. Ten µl cell lysate and
50 µl 20mM ammonium acetate/ 0.1% Triton X-100 were dispensed onto each array spot,
and incubated for one hour. The incubation comprised 60 cycles of pipetting the sample
mixture up and down for 30 s. Array spots were washed 3 × 5 min with 75 µl 20mM
ammonium acetate/ 0.1% Triton X-100 and 1 × 5 min with 75 µl water.
Immobilized metal affinity chromatography
Immobilized metal affinity capture arrays (IMAC30 ProteinChip™ arrays; Ciphergen) were
incubated with 100mM CuSO4 for 25 min and loaded onto a 192-well bioprocessor.
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Subsequently, the arrays were equilibrated with 50 mM NaCl, 100mM NaH2PO4, pH 7.0.
Ten µl cell lysate and 40 µl 50 mM NaCl, 100mM NaH2PO4, pH 7.0 were dispensed onto
each array spot and incubated for an hour. Array spots were washed 3 × 5 min with 75 µl
500 mM NaCl, 100mM NaH2PO4, pH 7.0 to remove non-specifically bound proteins and
then washed 5 minutes with 75 µl water.
Application of Matrix Molecule
SPA (sinapinic acid; Fluka), the matrix molecule, was prepared as a saturated solution in
50% acetonitrile/ 0.5% trifluoroacetic acid, and then diluted 1:1 in 50% acetonitrile/ 0.5%
trifluoroacetic acid. After air drying arrays, 2 × 1 µl and 2 × 0.75 µl of SPA were dispensed
to each spot of the hydrophobic, cationic exchange and IMAC arrays respectively, again
using the Biomek FX™ (Beckman Coulter) equipped with a 96-channel 200 µl head. The
arrays were air-dried again, and immediately analyzed.
Analysis
Peak detection—Protein peaks were defined by a signal-to-noise ratio >= 2.5 and
detected using the Ciphergen Biomarker Wizard software. We interrogated the range of
2,000 – 40,000 Da for peaks and normalized the peak data with the total ion current method
after baseline correction.
Data Set Split—The subjects were randomly divided into a training and validation set.
The training set was used as a test-bed to find the predictive signature (peaks predictive for
therapy response), which was then applied to the independent validation set, which had not
been previously used to identify the predictive signature. The training set consisted of 16
non-responders (8 lymph node positive, 8 lymph node negative) and 12 responders (2 lymph
node positive, 10 lymph node negative). The validation set consisted of 16 non-responders
(9 lymph node positive, 7 lymph node negative) and 12 responders (2 lymph node positive,
10 lymph node negative).
Class Prediction—We identified a set of descriptive peaks (differentially expressed peaks
between responders and non-responders) on the training data set using t-test (p<0.05),
assessed its significance using permutation testing (1000 permutations, 5% significance
level) and chose peaks that remained significant after permutation analysis to account for
multiple hypothesis testing13. The descriptive peaks were refined based on the accuracy of
its subsets as predictor peaks on the training set using leave-one-out cross validation. We
started this procedure on the training set with the responders and non-responders, and a set
of features, the descriptive peaks. A sample was left out and a predictor set of peaks that
distinguished the two groups was built and used to predict the class of the left-out sample.
This procedure was cycled through all samples individually. The accuracy of the predictor
equaled the total number of correctly predicted left-out samples. The best performing
(highest leave-one-out accuracy) subset of the descriptive peaks was chosen as the
predictive peak signature which was then applied to the validation set. Calculations of
descriptive and predictive peaks were done solely on the training test. The finalized set of
predictive peaks was then applied on the independent validation set, which was not used in
obtaining the predictive signature. Class prediction was done using the k-nearest neighbor
algorithm and the p-value for the predictor accuracy was calculated using Fisher’s exact
test13. The significance of the results was further assessed by a permutation test. The
Mantel-Haenszel test was performed to assess the association between the proteomic profile
and the IL-2 response status controlling for the effect of the lymph node status. Gene Cluster
2 (Whitehead Institute) and SPSS 11.0 were used as analysis software.
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Clustering—A hierarchical clustering technique was used to construct an Unweighted Pair
Group Method with Arithmetic-mean (UPGMA) tree using Pearson’s correlation as the
metric of similarity.
Results
The clinicopathological characteristics of the studied patients as well as the partitioning into
training and validation set are presented in Table 1. There were no parameters with a
statistically significant difference between training and validation set.
Out of the 56 metastatic patients 24 patients had responded and 32 patients had not
responded to IL-2 therapy. Of the 24 responders, there were 22 partial and 2 complete
responders according to RECIST.
Samples were spotted in duplicate and yielded highly reproducible spectra, as recently
shown11. The average intra-assay coefficient of variation was approximately 16%, which is
within an acceptable range for SELDI studies11. SELDI TOF-MS detected a total of 513
protein peaks on the ProteinChip™ arrays (165 on IMAC30, 206 on CM10 and 142 on
H50).
We identified 23 descriptive peaks that differentiated responders from non-responders in the
training set (p<0.05, permutation p<0.05). Figure 1 depicts the hierarchical clustering of the
samples in the validation set using the 11 peak signature. These peaks were obtained by
refinement of 23 descriptive peaks based on their leave-one-out prediction accuracy on the
training set. This 11 peak signature displayed 86% leave-one-out cross validation accuracy
(24/28 predicted correctly, p < 0.004; permutation p<0.001) for the response status of the
samples.
We then tested the 11-peak signature against samples in the validation set. The overall
accuracy was 72% (20/28 predicted correctly, p < 0.05, permutation p<0.01). Figure 2
presents a scattergram depicting the confidence values for prediction results for the training
and validation sets13.
The trace view from the SELDI-TOF spectra of one of the 11 predictor peaks is shown
representatively in Figure 3.
Because of the known association between lymph node status and response to IL-2 therapy,
we examined the possibility that our results were confounded by lymph node status. Lymph
node status was not associated with the SELDI predictions (Fisher’s p=0.245). Nonetheless,
we performed multivariate analysis, which further showed that SELDI predictions were
associated with IL-2 response independent of lymph node status (p=0.04 by Mantel
Haenszel test).
Discussion
The frustrating paucity of therapeutic options in metastatic RCC have led to the search for
biomarkers that can aid in predicting prognosis and in selecting patients for appropriate
therapy. Markers such as CAIX or Ki67 have been proposed for survival prediction in
RCC6. In addition to individual markers, prognostic algorithms for survival in RCC patients
have been developed through the use of select clinicopathological parameters such as 1997
classification T stage, Fuhrman’s grade or lymph node status14, 15. A more recent report
focusing on metastatic RCC patients described an algorithm for survival prediction in
patients after radical nephrectomy and IL-2 immunotherapy, which is to date considered the
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therapy most likely to result in durable complete remissions for patients with metastatic
RCC16.
IL-2 response, even when not complete, appears to be a surrogate for survival in metastatic
RCC patients17. Considering the substantial toxicity of IL-2 therapy and the lack of reliable
individual biomarkers for response, the objective of the current study was to discover a
protein profile that could in the future enable the identification of the small subset of patients
who are most likely to benefit from IL-2 therapy. This is to our knowledge the first report
attempting the prediction of IL-2 response in metastatic RCC patients using proteomic
analysis.
Using a highly standardized and automated procedure we used protein extracts from tumor
sample tissue lysates of clear cell RCC patients with distant metastases who had undergone
radical nephrectomy prior to receiving adjuvant IL-2 therapy, and applied them to three
protein chip arrays of different chromatographic properties. Analysis of protein profiles
revealed a pattern of 11 protein peaks predictive of IL-2 response that could be validated
with 72% accuracy in an independent sample set (66% accuracy for responders, 75% for
non-responders) (p<0.04). Interestingly, lymph node status, which has been reported to be
strongly associated with IL-2 immunotherapy response and is sometimes used in the clinical
setting8, was accurate in only 62.5 % of the same sample set, highlighting the shortcoming
of relying only on clinical variables to predict outcome. On multivariate analysis the result
of the protein pattern remained statistically significant when controlled for lymph node
status (p<0.01). Clustering analysis shows that the 11-peak predictive signature can
successfully distinguish between responders and non-responders (Figure 1).
Proteomic technologies, such as MS, provide the means to compare protein profiles
identifying diagnostic or prognostic protein signatures. Protein profiling using SELDI-TOF
MS has been successfully applied to derive protein signatures that distinguish several
neoplastic entities18. Despite the limitations of SELDI-TOF MS with regard to resolution
when compared to other MS technologies, the advantages of SELDI-TOF MS are the high
throughput and sensitive acquisition of protein profiles from large numbers of patient
samples in combination with on-chip protein fractionation that cannot be currently matched
by other MS technologies19. While SELDI-TOF MS cannot directly identify the proteins in
a protein profile, tandem MS is limited due to the requirement of extensive fractionation for
protein identification, thus, dramatically decreasing sample throughput.
Thus, we have identified in our sample set a proteomic pattern that distinguishes and
predicts IL-2 response and is an independent predictor of the lymph node status offering
additional information. The clinical value of this molecular predictor will have to be
validated prospectively in a larger independent data set. Our current study, however,
provides the first “proof of principle” that such a proteomic profile can predict IL-2 therapy
response in metastatic RCC patients.
High-dose IL-2 therapy produces tumor responses in 15–20% of metastatic RCC patients
but individual prediction of treatment response is unreliable17. Prior ability to predict IL-2-
response probability would allow the sparing of patients having a low probability of
response from unwanted toxicities, making them candidates for alternative, investigational
therapies. Future protein identification of some of the predictive peaks may, in addition,
offer insights into the mechanisms underlying IL-2 responsiveness, and eventually lead to
the development of alternative, more targeted treatment regimens.
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Key of Definitions for Abbreviations
RCC renal cell carcinoma
SELDI-TOF MS surface-enhanced laser desorption/ionization time-of-flight mass
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Figure 1.
Hierarchical clustering of the samples in the validation set using the 11-peak signature. R
and NR stand for Responder and Non-Responder respectively. The lymph node status
(lymph) is addressed by 0 and 1 as no cancer inflitration and present cancer infiltration,
respectively. Rows represent the intensity values of individual peaks, which are normalized
to [−1, 1] as shown in the scale at the bottom. Peak labels represent the chip on which the
peak was detected (I for IMAC30, C for CM10, H for H50) followed by the molecular
weight for the detected peak. Red denotes an elevation while green denotes a decrease in
expression.
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Figure 2.
Scattergram depicting the confidence values for prediction results for both the training (2a)
and validation sets (2b). X-axis is shown in bold red color denoting the separating line to
make a decision for the response status. Samples that are above the line are predicted as non-
responders and samples that are below the line are predicted as responders. True class labels
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along with lymph node status are shown below each data point. Samples that are predicted
in error are depicted using a colored background for the respective data labels.
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Figure 3.
Trace view for one representative peak I 3606_65 (representing the peak on the IMAC30
chip with a molecular weight of 3,606.65 Da) from the 11-peak signature. The detection
level for the peak (boxed) in 8 responders (R) and 8 non-responders (NR) is shown.
Zooming of a spectrum shows the peak of interest as a picture in picture.
Jones et al. Page 12
J Urol. Author manuscript; available in PMC 2013 November 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Jones et al. Page 13
Table 1
Clinical and pathological characteristics of all patients.
Total no. of patients 56
Gender* Male 41 /
Female 15
Age* Median 55
years (34–75)
Histologic subytpe* Clear cell
Response status Responder (24**)
Non-Responder
(32)
Lymph node status N+ (21)
N0 (35)
Data set split Training Validation
n 28 28
Response Status*
Lymph Node Status*
12 Responders
2 LN +
12 Responders
2 LN+
10 LN − 10 LN −
16 Non-Responders
8 LN +
16 Non-Responders
7 LN+
8 LN − 9 LN −
*Not significantly different in training and validation set (p>0.05)
**22 partial and 2 complete responders according to RECIST
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